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Table 2
Mean number of infections per patient.
Age 0-2 2-5 >5
n[79 n[58 n[170 p-value
GPC 0.37 0.59 0.36 0.27
GNR 0.35 0.12 0.3 0.23
Viral 0.72 1.28 1.34 0.0002
Adeno 0.15 0.38 0.25 0.03
BK 0.03 0.1 0.33 <0.0001
CMV 0.17 0.33 0.39 0.08
EBV 0.4 0.41 0.43 0.96
HHV6 0.06 0.14 0.07 0.3
Flu 0.06 0 0.04 0.19
Metapneumo 0.04 0.03 0.05 0.81
Noro 0.09 0.1 0.08 0.9
Paraﬂu 0.03 0.07 0.06 0.46
Parvo 0 0 0.05 0.06
Rhino 0.1 0.07 0.07 0.71
Rota 0.03 0 0.02 0.5
RSV 0.06 0.1 0.12 0.5
Other 0 0 0.01 0.67
GPC- gram positive cocci, GNR- gram negative rod, UTI- urinary tract
infection, CMV- cytomegalovirus, EBV- Epstein-Barr virus, HHV6- human
herpes virus 6, Flu- Inﬂuenza A or B, RSV- respiratory syncytial virus
Figure 1. The correlationbetween infectionsbefore transplantationandsurvival.
Figure 2. Results according to conditioning regimen.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S235Results: Patients were divided into age groups: 0-2yrs
(n¼79), 2-5yrs (n¼58) and>5yrs (n¼170). Table 1 shows the
number and type of infection per group. Viral infections
differed signiﬁcantly between the 0-2, 2-5 and >5 year age
groups (0.72, 1.28, 1.34, respectively) (Table 2). The
incidence of adenovirus and BK virus was lower amongst
those aged 0-2 years (0.15 and 0.03) compared to those
aged 2-5 years (0.38 and 0.1) and those aged >5 years
(0.25 and 0.33) respectively.
There was no difference in the rates of bacteremia or
fungal infections.
Conclusion: We demonstrate there is a signiﬁcantly lower
rate of viral infections in children <2yrs of age undergoing
allogeneic HSCT. It is surprising to note the reduced inci-
dence of adenovirus in children <2 years, though the dif-
ference in BK virusmay be explained by the natural history of
acquisition of the virus. The overall difference may be related
to their younger age at HSCT and low infectious burden
compared to other age groups. Careful monitoring and pro-
phylaxis for high risk individuals is necessary to further
reduce morbidity and mortality associated with infections in
this fragile population.
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SCID is a group of inherited diseases with genetic defects
characterized by severe abnormalities in the immune sys-
tem. The only potential cure is allogeneic hematopoietic
stem cell transplantation (SCT) and in rare cases gene
therapy.
Our objective herein was to review the outcome of factors
determining outcome of all children who received SCT for adiagnosis of SCID in Rambam Medical Center, Israel. From
1996 to 2013 twenty children with different genetic types of
SCID underwent SCT. Median age at SCT for 19 childrenwas 8
months; 1 child was transplanted at age of 14 years due to
loss of graft. Median time from diagnosis to SCT was 2
months.
11 children had graft from matched family donor, 6 from
sibling and 5 from other family members, 4-unrelated cord
and 5-Haploidentical SCT. Protocol regimen before SCT
included Busulphan-based in 50% of patients, 25% were
transplanted without conditioning regimen and 25% chil-
dren received Treosulphan based protocol. Overall survival
was 60%. Almost all survived children underwent SCT with
Busulphan conditioning regimen died from transplant
related complications. Most of the patients that were diag-
nosed late had severe infections before SCT. 6 children were
early diagnosed due to family history of SCID. They didn’t
suffer from any infections prior to transplantation and all
are alive (Figure 1). Better prognosis was also in a group
with Treosulphan based conditioning regimen (Figure 2).
Incidence of acute graft-versus host disease (GVHD)
was 15%.
Allogeneic SCT is effective for cure and survival in SCID pa-
tients. Early diagnosis of SCID and performing SCT before the
appearance of severe infection, as well as reduced toxicity
regimen will improve signiﬁcantly survival. Development of
new protocols with low toxicity drugs for Conditioning
regimen and newborn screening for SCID are needed for
highly favorable outcome.
